A novel therapeutic target, GPR43: where it stands in drug discovery = 신약 타겟 GPR43

Cited 10 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorSunhong Kim-
dc.contributor.authorY M Kim-
dc.contributor.authorYoung Shin Kwak-
dc.date.accessioned2017-04-19T09:33:56Z-
dc.date.available2017-04-19T09:33:56Z-
dc.date.issued2012-
dc.identifier.issn02536269-
dc.identifier.uri10.1007/s12272-012-0900-6ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/10954-
dc.description.abstractWith growing interest in human microbiome for its implication in metabolic disorders, inflammatory diseases, immune disorders and so forth, understanding the biology at the interface of the gut flora and the host becomes very important for identifying novel therapeutic avenues. GPR43 has been deorphanized and the metabolites of microbiome, such as short-chain fatty acids, serve as its natural ligands. There are numerous reports that GPR43 might be a crucial link to the novel therapies for the unmet medical needs and many drug discovery organizations are making their moves in response.-
dc.publisherPharmaceutical Soc Korea-
dc.titleA novel therapeutic target, GPR43: where it stands in drug discovery = 신약 타겟 GPR43-
dc.title.alternativeA novel therapeutic target, GPR43: where it stands in drug discovery-
dc.typeArticle-
dc.citation.titleArchives of Pharmacal Research-
dc.citation.number9-
dc.citation.endPage1509-
dc.citation.startPage1505-
dc.citation.volume35-
dc.contributor.alternativeName김선홍-
dc.contributor.alternativeName김유미-
dc.contributor.alternativeName곽영신-
dc.identifier.bibliographicCitationArchives of Pharmacal Research, vol. 35, no. 9, pp. 1505-1509-
dc.identifier.doi10.1007/s12272-012-0900-6-
dc.description.journalClassY-
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.